Detailed explanation of the efficacy and side effects management of ceritinib

Introduction: Ceritinib is a second-generation targeted drug for lung cancer and an anaplastic lymphoma kinase (ALK) inhibitor. It is used to treat locally advanced or metastatic ALK fusion-positive non-small cell lung cancer (NSCLC) that has progressed after previous treatment with crizotinib or is intolerant to crizotinib. This article mainly talks about the efficacy, mechanism of action, side effects and management of ceritinib.

Efficacy

Ceritinib can significantly improve the quality of life of patients and has a significant effect on disease control in patients with ALK-positive non-small cell lung cancer. The study found that the survival rate and survival time of patients treated with ceritinib were significantly improved compared with conventional chemotherapy. In addition, ceritinib can also be used to treat patients with metastatic or recurrent lung cancer and has a certain therapeutic effect.

Mechanism of action

Ceritinib is a kinase inhibitor that inhibits targets including ALK, insulin receptor and c-ROS oncogene (ROS1), and has the strongest inhibitory activity against ALK. It inhibits ALK autophosphorylation and ALK-mediated phosphorylation of the downstream signaling protein STAT3, thereby achieving anti-tumor effects. By blocking the abnormal division and growth of cancer cells, it helps control the development of lung cancer and improves the survival rate of patients.

Side effects and management

1. Gastrointestinal reactions: Symptoms of digestive discomfort such as diarrhea, nausea, vomiting, abdominal pain, and constipation may occur. In rare cases, it may lead to serious problems such as pancreatitis and gastrointestinal bleeding. If the related gastrointestinal reactions are serious, please inform your doctor in time.

2. Liver and kidney damage: Specific manifestations include abnormalities in biochemical indicators such as elevated bilirubin, creatinine, alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Occasionally, it can lead to serious problems such as acute kidney injury and cholestatic hepatitis. If the patient's urine output decreases, the color of his urine becomes darker, or his skin or eyes turn yellow while taking the medicine, he should seek medical treatment in time.

3. Blood system abnormalities: reduced hemoglobin, hypophosphatemia, etc. may occur. If you experience symptoms such as fatigue, shortness of breath, palpitation, fatigue, dizziness, or pale complexion in your daily life, please go to the hospital for relevant examinations in time.

4. Metabolic system abnormalities: Some patients lose appetite and weight after taking the drug, and sometimes hyperglycemia may occur. Fasting serum glucose should be monitored before the start of treatment, and then monitored regularly according to clinical indications, and treated with antidiabetic drugs.

5. Other adverse reactions: Some people may also experience rashes, visual impairment, etc. In a few cases, serious side effects may occur, such as QT interval prolongation of the cardiovascular system, pulmonary toxicity of the respiratory system, pancreatic inflammation, liver damage, etc. These serious side effects are generally difficult to relieve or subside on their own.

During the use of , patients should pay close attention to their physical condition and report any discomfort or abnormal reactions to their doctor in a timely manner. Doctors will adjust the treatment plan based on the patient's specific situation to minimize side effects and improve treatment effectiveness.